Global Blood Therapeutics, Inc.
GBT · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Market Cap | $2 | $3 | $5 | $2 |
| - Cash | $1 | $0 | $0 | $0 |
| + Debt | $1 | $0 | $0 | $0 |
| Enterprise Value | $2 | $2 | $4 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 57.3% | 5,773% | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 98.3% | 98.4% | 97.7% | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -143% | -183.3% | -12,183.8% | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -155.6% | -200% | -12,654.9% | – |
| EPS Diluted | -4.82 | -4.04 | -4.57 | -3.41 |
| % Growth | -19.3% | 11.6% | -34% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |